Premium
Feeding of probiotic formulation protects from obesity and diabetes
Author(s) -
Yadav Hariom,
Rane Sushil G
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.1155.4
Subject(s) - endocrinology , ghrelin , leptin , medicine , adipokine , obesity , diabetes mellitus , energy homeostasis , gut flora , adiponectin , adipose tissue , dyslipidemia , glucose homeostasis , insulin resistance , type 2 diabetes , diet induced obese , insulin , hormone , immunology
The role of gut flora in obesity and diabetes is an area of active debate. We found that feeding of probiotic formulations (i.e. Culturelle, Primal, VSL#3, Pb8 and Ultimate 10 probiotics) protect high fat diet (HFD)‐induced obesity and insulin resistance in mice. VSL#3 exhibited the best anti‐obese/diabetes potential in terms of reducing weight gain, fat mass and dyslipidemia. VSL#3 treated mice exhibit improved glucose homeostasis characterized by enhanced insulin sensitivity and glucose tolerance. Interestingly, VSL#3 treated mice dramatically decreased daily food/energy intake. Moreover, VSL#3 treatment modulated the gut‐brain axis by altering the levels of gut hormones and adipokines that regulate food intake and energy homeostasis. Specifically, VSL#3 treatment decreased ghrelin levels and increased PYY, GLP‐1, leptin and adiponectin levels in HFD‐fed mice. In line with these results, VSL#3 treatment enhanced phosphorylation levels of the leptin signaling mediator, STAT3. Further, we observed changes in expression of hypothalmic genes that regulate food intake. Thus, reduced expression of Npy and Agrp and increased Pomc expression was seen in the hypothalamus of VSL#3‐treated mice. These results provide a proof of concept that feeding of probiotics can be potential therapeutic approach to protect from obesity and diabetes via modulation of gut‐brain axis and adipose biology.